Abstract: The disclosure provides methods for estimating tumor purity from tumor samples without use of matched-normal controls. A set of genomic regions are identified based on a nucleic acid sequence data that is aligned to a reference genome. Each genomic region of the set of genomic regions includes one or more nucleotide-sequence variants relative to a corresponding genomic region of the reference genome. A B-allele frequency distribution for the biological sample is determined based on a B-allele frequency determined for each genomic region of the set of genomic regions. The B-allele frequency distribution is processed using a trained machine-learning model to estimate a metric identifying tumor purity in the biological sample.

Abstract: The following relates generally to facilitating order and delivery of prescription medication. In some embodiments, a first prescription for a first medication of a first patient is received; and a second prescription for a second medication of a second patient is received. A pickup time of a first pharmacy may then be determined by: determining a pickup time for the first medication at the first pharmacy; determining a pickup time for the second medication at the first pharmacy; and selecting, as the pickup time of the first pharmacy, the later of the pickup time for the first medication and the pickup time for the second medication. Identifications of all of: the first patient, the second patient, the first medication, the second medication, the first pharmacy, and the pickup time of the first pharmacy may then be displayed.

Abstract: Example methods, apparatus, and articles of manufacture to estimate waiting times of prescriptions are disclosed herein. An example computer-implemented method, executed by a processor, to estimate a waiting time of a prescription for a medication includes training a machine learning model using, for each of a plurality of previously filled prescriptions, a set of characteristics of the previously filled prescription, and a fill time for the previously filled prescription, receiving a prescription for a medication for a patient, receiving a request for an estimated waiting time for filling the prescription medication for the patient, identifying a set of characteristics of the prescription medication for the patient, applying the set of characteristics of the prescription medication to the machine learning model to determine the estimated waiting time for filling the prescription medication for the patient, and providing an indication of the estimated waiting time for display on a client device.

Abstract: An analysis container includes an outer tube and a plurality of inner tubes. The outer tube defines a buffer volume that is configured to receive a buffer material. The plurality of inner tubes is disposed within the buffer volume. Each inner tube has an inner diameter equal to or less than 6 mm and is configured to receive a biopharmaceutical composition therein. The outer tube is configured such that the buffer material and the biopharmaceutical composition are axially frozen.

Abstract: Example methods, apparatus, and articles of manufacture to estimate waiting times of prescriptions are disclosed herein. An example computer-implemented method, executed by a processor, to estimate a waiting time of a prescription for a medication includes training a machine learning model using, for each of a plurality of previously filled prescriptions, a set of characteristics of the previously filled prescription, and a fill time for the previously filled prescription, receiving a prescription for a medication for a patient, receiving a request for an estimated waiting time for filling the prescription medication for the patient, identifying a set of characteristics of the prescription medication for the patient, applying the set of characteristics of the prescription medication to the machine learning model to determine the estimated waiting time for filling the prescription medication for the patient, and providing an indication of the estimated waiting time for display on a client device.

Abstract: Methods for somatic variant calling from an unmatched biological samples is provided. The method can include obtaining nucleic acid sequence data corresponding to a biological sample of a subject. The method can also include aligning the nucleic acid sequence data to a reference genome. The method can also include identifying, based on the aligned nucleic acid sequence data, a set of candidate variants in said nucleic acid sequence data. The set of candidate variants may include one or more somatic variants and one or more germline variants. The method can also include, without using a nucleic acid sequencing data from a matching biological sample of the subject, processing the set of candidate variants using a trained machine-learning model to identify the somatic variants. The method can also include outputting a report that identifies the somatic variants.

Abstract: A weight lifting bar, such as a pull-up bar is provided. The pull-up bar may be wall-mounted or utilized with a power rack. The bar includes a cylindrical bar, which is typically made of steel. The bar further includes a sand-blasted finish applied to the cylindrical bar. The sand-blasted finish creates a layer over at least a portion of the cylindrical bar.

Abstract: The invention is directed to a sensor apparatus for determining when a water outlet needs flushing, comprising a water flow monitoring sensor adapted to be in contact with a source of water flowing through a conduit; a microprocessor in electronic communication with the water flow monitoring sensor, the microprocessor configured to calculate whether the water stagnation time exceeds a predetermined threshold; and indicia for signaling when the water needs flushing by a user, the indicia n electronic communication with the microprocessor. The water flow monitoring sensor may include an accelerometer for detecting water flow vibrations typical of water flow in water conduits. A microprocessor calculates and tracks the total flush time since the prior flush of a drinking water source, thereby monitoring its safety for users of the water source.

Abstract: In an exemplary embodiment, an apparatus for a sustainable clip is shown and described. The sustainable clip may be formed from compressed board. The sustainable clip may be formed to provide a functionality that is the same or improved over known clips, while also decreasing manufacture cost and reducing waste associated with those clips.

Abstract: The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein A1a, A1b, R1, R2, R3 and R4 and R5 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), and to their use for controlling weeds, in particular in crops of useful plants.

Abstract: The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein A1a, A1b, R1, R2, R3 and R4 and R5 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), and to their use for controlling weeds, in particular in crops of useful plants.

Abstract: The present invention relates to compounds of formula (I), or an agronomically acceptable salt of said compounds wherein A1a, A1b, R1, R2, R3, R4, R5 and R6 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), and to their use for controlling weeds, in particular in crops of useful plants.

Abstract: The present invention relates to compounds of formula (I), or an agronomically acceptable salt of said compounds wherein A1a, A1b, R1, R2, R3, R4, R5 and R6 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), and to their use for controlling weeds, in particular in crops of useful plants.

Abstract: The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein A1, A2, R1, R2, R3 and R4 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controlling weeds, in particular in crops of useful plants, and to intermediates used to synthesize said compounds.

Abstract: The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein A1, A2, R1, R2, R3 and R4 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controlling weeds, in particular in crops of useful plants, and to intermediates used to synthesise said compounds.

Abstract: The present invention provides stereoselective processes for the preparation of compounds of formula (I) wherein P is phenyl, naphthyl, a 6-membered heteroaryl group containing one or two nitrogen atoms as ring members, or a 10-membered bicyclic heteroaryl group containing one or two nitrogen atoms as ring members, and wherein the phenyl, naphthyl and heteroaryl groups are optionally substituted; R1 is chlorodifluoromethyl or trifluoromethyl; R2 is optionally substituted aryl or optionally substituted heteroaryl; n is 0 or 1; including the process comprising (a-i) reacting a compound of formula II wherein P, R1 and R2 are as defined for the compound of formula I; with nitromethane in the presence a chiral catalyst to give a compound of formula III wherein P, R1 and R2 are as defined for the compound of formula I; and (a-ii) reductively cyclising the compound of formula III to give the compound of formula I.

Abstract: The present invention provides stereoselective processes for the preparation of compounds of formula (I) wherein P is phenyl, naphthyl, a 6-membered heteroaryl group containing one or two nitrogen atoms as ring members, or a 10-membered bicyclic heteroaryl group containing one or two nitrogen atoms as ring members, and wherein the phenyl, naphthyl and heteroaryl groups are optionally substituted; R1 is chlorodifluoromethyl or trifluoromethyl; R2 is optionally substituted aryl or optionally substituted heteroaryl; n is 0 or 1; including the process comprising (a-i) reacting a compound of formula II wherein P, R1 and R2 are as defined for the compound of formula I; with nitromethane in the presence a chiral catalyst to give a compound of formula III Wherein P, R1 and R2 are as defined for the compound of formula I; and (a-ii) reductively cyclizing the compound of formula III to give the compound of formula I.

Abstract: A fracture reduction implant for treating a vertebral compression fracture and instruments and methods for implanting the fracture reduction device utilizing a minimally invasive lateral approach are described. The implant may be inserted into a fractured vertebra through a T-shaped cut formed in the vertebral wall. The T-shaped cut may be formed in the lateral aspect of the wall. After insertion, a portion of the implant may be elevated within the vertebral body to reduce the fracture. The implant may include a base assembly, elevator plate, and a support column. The support column may be locked to the base assembly after insertion.